<p>Twist Bioscience Corporation（纳斯达克代码：TWST - 获取免费报告）在周二的午盘交易中股价下跌了 4.1%。该公司的股价最低曾达到 33.58 美元，最后交易价为 33.6320 美元。午盘交易中大约有 39,548 股成交，较日均成交量 1,346,963 股下降了 97%。该股票此前收盘价为 35.06 美元。</p>
<p>获取 <strong>Twist Bioscience</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>几位股票分析师最近对该股进行了评估。Stephens 在 11 月 3 日的研究报告中开始覆盖 Twist Bioscience 的股票。他们给予该股 “增持” 评级，目标价为 41.00 美元。Evercore ISI 在 10 月 7 日的报告中将 Twist Bioscience 的目标价从 46.00 美元下调至 42.00 美元，并给予公司 “跑赢大盘” 评级。Weiss Ratings 在 12 月 15 日的报告中重申了 Twist Bioscience 的 “卖出（d-）” 评级。最后，巴克莱在 12 月 15 日的研究报告中将 Twist Bioscience 的目标价从 37.00 美元上调至 39.00 美元，并给予公司 “增持” 评级。八位研究分析师对该股给予了买入评级，两位分析师对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 44.88 美元。</p>
<p><strong>获取我们对 Twist Bioscience 的最新股票分析</strong></p>
<h2>Twist Bioscience 股价下跌 4.3%</h2>
<p>该公司的 50 日简单移动平均线为 31.02 美元，200 日简单移动平均线为 31.19 美元。该公司的市值为 20.5 亿美元，市盈率为-25.66，贝塔值为 2.24。该公司的债务与股本比率为 0.03，流动比率为 3.64，速动比率为 3.33。</p>
<p>Twist Bioscience（纳斯达克代码：TWST - 获取免费报告）最近在 11 月 14 日发布了其财报。该公司报告每股收益为（0.45 美元），低于市场共识预期的（0.40 美元）0.05 美元。Twist Bioscience 的净利润率为-20.63%，股本回报率为-27.40%。该公司在本季度的收入为 9901 万美元，而分析师预期为 9740 万美元。整体来看，卖方分析师预计 Twist Bioscience Corporation 在当前财政年度将发布-2.12 的每股收益。</p>
<h2>Twist Bioscience 的内部活动</h2>
<p>在其他 Twist Bioscience 的新闻中，首席执行官 Emily M. Leproust 在 11 月 3 日的交易中出售了 4,887 股该股票。股票以平均价格 32.08 美元出售，总交易额为 156,774.96 美元。出售后，首席执行官直接持有 733,922 股公司股票，价值 23,544,217.76 美元。这代表其持股比例下降了 0.66%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，高级副总裁 Paula Green 在 11 月 3 日的交易中出售了 1,084 股公司的股票。该股票以平均价格 32.08 美元出售，总价值为 34,774.72 美元。出售后，高级副总裁直接持有 142,187 股公司股票，价值 4,561,358.96 美元。这代表其持股比例下降了 0.76%。该销售的 SEC 备案提供了更多信息。在过去三个月中，内部人士出售了 116,878 股公司股票，价值 3,721,723 美元。公司内部人士持有 3.01% 的股票。</p>
<h2>机构投资者对 Twist Bioscience 的看法</h2>
<p>大型投资者最近买入和卖出了该股票的股份。Quarry LP 在第三季度新购入了 Twist Bioscience 的股份，价值约 28,000 美元。Smartleaf Asset Management LLC 在第三季度将其在 Twist Bioscience 的持股增加了 70.6%。Smartleaf Asset Management LLC 现在持有 1,068 股公司股票，价值 29,000 美元，此前在上个季度又购买了 442 股。加拿大国家银行 FI 在第三季度购买了 Twist Bioscience 的新股份，价值约 46,000 美元。Mirae Asset Global Investments Co. Ltd.在第二季度将其在 Twist Bioscience 的持股增加了 15.0%。Mirae Asset Global Investments Co. Ltd.现在持有 2,315 股公司股票，价值 85,000 美元，此前在上个季度又购买了 302 股。最后，Geneos Wealth Management Inc.在第二季度购买了 Twist Bioscience 的新股份，价值 97,000 美元。</p>
<h2>Twist Bioscience 公司简介</h2>
<p>（获取免费报告）</p>
<p>Twist Bioscience Corporation 是一家合成生物学公司，专注于 DNA 基础产品和解决方案的开发与商业化。公司成立于 2013 年，总部位于加利福尼亚州南旧金山，开创了一种专有的基于硅的 DNA 合成平台，旨在高通量生产合成基因和寡核苷酸。Twist 利用半导体制造技术，实现了传统方法无法达到的精确、可扩展的 DNA 合成速度和产量。</p>
<p>Twist 的核心产品是其专有平台，能够自动合成定制的 DNA 片段、基因库和长寡核苷酸。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Twist Bioscience</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “3 美元 AI 奇迹股票” 即将腾飞</li>
<li>埃隆警告 “美国破产”。特朗普的计划在此。</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Twist Bioscience 吗？</h2>
<p>在考虑 Twist Bioscience 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而 Twist Bioscience 并不在名单上。</p>
<p>虽然 Twist Bioscience 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TWST

<p>Twist Bioscience 的股票（NASDAQ:TWST）在午盘交易中下跌了 4.1%，交易量显著减少。分析师的评级不一，有些维持 “买入”，而另一些则为 “卖出”。该公司报告了季度亏损，未能达到预期，内部人士最近出售了股份。机构投资者调整了他们的持仓，有些增加了持股。Twist Bioscience 专注于基于 DNA 的产品，使用专有的合成平台</p>

<p>Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report)'s share price dropped 4.1% during mid-day trading on Tuesday . The company traded as low as $33.58 and last traded at $33.6320. Approximately 39,548 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 1,346,963 shares. The stock had previously closed at $35.06.</p>
<div class="lb-trans"><p>Twist Bioscience Corporation（纳斯达克代码：TWST - 获取免费报告）在周二的午盘交易中股价下跌了 4.1%。该公司的股价最低曾达到 33.58 美元，最后交易价为 33.6320 美元。午盘交易中大约有 39,548 股成交，较日均成交量 1,346,963 股下降了 97%。该股票此前收盘价为 35.06 美元。</p>
</div><p>Get <strong>Twist Bioscience</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Twist Bioscience</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities analysts have recently weighed in on the stock. Stephens initiated coverage on shares of Twist Bioscience in a research note on Monday, November 3rd. They issued an &#34;overweight&#34; rating and a $41.00 price target on the stock. Evercore ISI cut their price objective on shares of Twist Bioscience from $46.00 to $42.00 and set an &#34;outperform&#34; rating for the company in a report on Tuesday, October 7th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Twist Bioscience in a report on Monday, December 15th. Finally, Barclays upped their price target on Twist Bioscience from $37.00 to $39.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, December 15th. Eight research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $44.88.</p>
<div class="lb-trans"><p>几位股票分析师最近对该股进行了评估。Stephens 在 11 月 3 日的研究报告中开始覆盖 Twist Bioscience 的股票。他们给予该股 “增持” 评级，目标价为 41.00 美元。Evercore ISI 在 10 月 7 日的报告中将 Twist Bioscience 的目标价从 46.00 美元下调至 42.00 美元，并给予公司 “跑赢大盘” 评级。Weiss Ratings 在 12 月 15 日的报告中重申了 Twist Bioscience 的 “卖出（d-）” 评级。最后，巴克莱在 12 月 15 日的研究报告中将 Twist Bioscience 的目标价从 37.00 美元上调至 39.00 美元，并给予公司 “增持” 评级。八位研究分析师对该股给予了买入评级，两位分析师对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 44.88 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Twist Bioscience</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Twist Bioscience 的最新股票分析</strong></p>
</div><h2>Twist Bioscience Trading Down 4.3%</h2>
<div class="lb-trans"><h2>Twist Bioscience 股价下跌 4.3%</h2>
</div><p>The company's 50 day simple moving average is $31.02 and its two-hundred day simple moving average is $31.19. The company has a market cap of $2.05 billion, a PE ratio of -25.66 and a beta of 2.24. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.64 and a quick ratio of 3.33.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 31.02 美元，200 日简单移动平均线为 31.19 美元。该公司的市值为 20.5 亿美元，市盈率为-25.66，贝塔值为 2.24。该公司的债务与股本比率为 0.03，流动比率为 3.64，速动比率为 3.33。</p>
</div><p>Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. The company had revenue of $99.01 million during the quarter, compared to analyst estimates of $97.40 million. As a group, sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Twist Bioscience（纳斯达克代码：TWST - 获取免费报告）最近在 11 月 14 日发布了其财报。该公司报告每股收益为（0.45 美元），低于市场共识预期的（0.40 美元）0.05 美元。Twist Bioscience 的净利润率为-20.63%，股本回报率为-27.40%。该公司在本季度的收入为 9901 万美元，而分析师预期为 9740 万美元。整体来看，卖方分析师预计 Twist Bioscience Corporation 在当前财政年度将发布-2.12 的每股收益。</p>
</div><h2>Insider Activity at Twist Bioscience</h2>
<div class="lb-trans"><h2>Twist Bioscience 的内部活动</h2>
</div><p>In other Twist Bioscience news, CEO Emily M. Leproust sold 4,887 shares of the stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $32.08, for a total transaction of $156,774.96. Following the sale, the chief executive officer directly owned 733,922 shares in the company, valued at $23,544,217.76. This represents a 0.66% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. Also, SVP Paula Green sold 1,084 shares of the company's stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $32.08, for a total value of $34,774.72. Following the sale, the senior vice president directly owned 142,187 shares in the company, valued at $4,561,358.96. This represents a 0.76% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 116,878 shares of company stock valued at $3,721,723. 3.01% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Twist Bioscience 的新闻中，首席执行官 Emily M. Leproust 在 11 月 3 日的交易中出售了 4,887 股该股票。股票以平均价格 32.08 美元出售，总交易额为 156,774.96 美元。出售后，首席执行官直接持有 733,922 股公司股票，价值 23,544,217.76 美元。这代表其持股比例下降了 0.66%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，高级副总裁 Paula Green 在 11 月 3 日的交易中出售了 1,084 股公司的股票。该股票以平均价格 32.08 美元出售，总价值为 34,774.72 美元。出售后，高级副总裁直接持有 142,187 股公司股票，价值 4,561,358.96 美元。这代表其持股比例下降了 0.76%。该销售的 SEC 备案提供了更多信息。在过去三个月中，内部人士出售了 116,878 股公司股票，价值 3,721,723 美元。公司内部人士持有 3.01% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Twist Bioscience</h2>
<div class="lb-trans"><h2>机构投资者对 Twist Bioscience 的看法</h2>
</div><p>Large investors have recently bought and sold shares of the stock. Quarry LP acquired a new position in shares of Twist Bioscience during the third quarter worth about $28,000. Smartleaf Asset Management LLC increased its position in shares of Twist Bioscience by 70.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company's stock valued at $29,000 after purchasing an additional 442 shares during the last quarter. National Bank of Canada FI purchased a new stake in shares of Twist Bioscience in the 3rd quarter valued at approximately $46,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock valued at $85,000 after purchasing an additional 302 shares in the last quarter. Finally, Geneos Wealth Management Inc. purchased a new stake in shares of Twist Bioscience during the 2nd quarter worth $97,000.</p>
<div class="lb-trans"><p>大型投资者最近买入和卖出了该股票的股份。Quarry LP 在第三季度新购入了 Twist Bioscience 的股份，价值约 28,000 美元。Smartleaf Asset Management LLC 在第三季度将其在 Twist Bioscience 的持股增加了 70.6%。Smartleaf Asset Management LLC 现在持有 1,068 股公司股票，价值 29,000 美元，此前在上个季度又购买了 442 股。加拿大国家银行 FI 在第三季度购买了 Twist Bioscience 的新股份，价值约 46,000 美元。Mirae Asset Global Investments Co. Ltd.在第二季度将其在 Twist Bioscience 的持股增加了 15.0%。Mirae Asset Global Investments Co. Ltd.现在持有 2,315 股公司股票，价值 85,000 美元，此前在上个季度又购买了 302 股。最后，Geneos Wealth Management Inc.在第二季度购买了 Twist Bioscience 的新股份，价值 97,000 美元。</p>
</div><h2>Twist Bioscience Company Profile</h2>
<div class="lb-trans"><h2>Twist Bioscience 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.</p>
<div class="lb-trans"><p>Twist Bioscience Corporation 是一家合成生物学公司，专注于 DNA 基础产品和解决方案的开发与商业化。公司成立于 2013 年，总部位于加利福尼亚州南旧金山，开创了一种专有的基于硅的 DNA 合成平台，旨在高通量生产合成基因和寡核苷酸。Twist 利用半导体制造技术，实现了传统方法无法达到的精确、可扩展的 DNA 合成速度和产量。</p>
</div><p>At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.</p>
<div class="lb-trans"><p>Twist 的核心产品是其专有平台，能够自动合成定制的 DNA 片段、基因库和长寡核苷酸。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Twist Bioscience</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Twist Bioscience</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “3 美元 AI 奇迹股票” 即将腾飞</li>
<li>埃隆警告 “美国破产”。特朗普的计划在此。</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Twist Bioscience Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Twist Bioscience 吗？</h2>
</div><p>Before you consider Twist Bioscience, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Twist Bioscience 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而 Twist Bioscience 并不在名单上。</p>
</div><p>While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Twist Bioscience 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Twist Bioscience（NASDAQ:TWST）股价下跌 4.1% - 现在是卖出的时候吗？